Sign in
Active, not recruitingNo phase

Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control

Key facts

Who runs it
Zhongshan Ophthalmic Center, Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
112 people, planned
Started
21 Sept 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ortho-k lenses
  • 0.01% Atropine
Record updated
18 August 2026

Who can take part

Age
8 years to 15 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Aged 8-15 years old
  • Spherical equivalent refractions (SERs) -0.50 to -6.00 Dioptres (D) and astigmatism less than -1.5 D in both eyes, anisometropia less than 1.5 D
  • Best corrected visual acuity (BCVA) equal to or better than 20/25 in both eyes
  • Bilateral intra-ocular pressure < 21mmHg
  • Normal binocular and stereoscopic visual function
  • Participants and their guardians' understanding and acceptance of random allocation of grouping

Who cannot take part

  • Previous use of myopia control without washout, including atropine, myopia control spectacles, myopia control contact lenses
  • Ocular or systemic diseases which may affect vision or refractive error
  • Manifest strabismus, except for intermittent tropia
  • Other contraindications

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this multicenter randomized clinical trial is to evaluate the myopia control effect of orthokeratology and 0.01% atropine sequential treatment in children and adolescents, as compared to continuous treatment with orthokeratology.

The 2 groups in the trial

  • Ortho-k and 0.01% atropine sequential treatmentTreatment being tested

    Participants will be treated with ortho-k lenses during the first year, and swiched to recieve 0.01% atropine twice a day in the second year.

    Treatment: Ortho-k lenses and 0.01% Atropine

  • Ortho-k continuous treatmentExisting treatment, for comparison

    Participants will be treated with ortho-k lenses throughout, during the 2-year study period.

    Treatment: Ortho-k lenses

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Myopia Control Effect of Orthokeratology and 0.01% Atropine Sequential Treatment in Children and Adolescents: A Multicenter Randomized Controlled Trial
Record updated
18 August 2026